Q1 2024 Earnings Summary
- Robust Decipher Growth: The Q&A highlighted 36% year-over-year revenue growth in Decipher, driven by strong market penetration and favorable updated NCCN guidelines along with new payer contracts that expand access to additional patient segments (e.g., an extra 30,000 metastatic patients), underscoring a durable multi-year growth trajectory.
- Enhanced Afirma Offering: Executives emphasized that enhancements like Afirma GRID and TERT have broadened the test’s clinical utility and adoption, helping penetrate both academic settings and rural markets. This improved diagnostic capability is expected to support continued revenue and volume growth.
- Diversified Pipeline for Long-Term Growth: The discussion pointed to significant pipeline initiatives, such as the MRD test for muscle invasive bladder cancer scheduled for launch in early 2026, along with other global IVD development efforts. These initiatives diversify the product portfolio and position the company for future revenue expansion.
- Slow enrollment in key clinical trials: The NIGHTINGALE trial is experiencing slower-than-expected patient enrollment per site, which could delay study completion and subsequent product commercialization efforts for the Percepta nasal swab test.
- Dependence on reimbursement and contract approvals: The company’s growth, particularly for Decipher, relies on favorable outcomes from significant payer contracts and reimbursement decisions, such as pending Medicare LCD finalizations for metastatic prostate cancer. Any delays or setbacks could adversely affect revenue growth.
- Limited revenue impact from Afirma enhancements: The recent addition of TERT and related updates to Afirma are expected to provide only modest improvements in average selling price (ASP), suggesting challenges in significantly boosting revenue from this segment.
-
Decipher Growth
Q: What drives Decipher's growth?
A: Management explained that Decipher is growing strongly, with approximately 36% revenue growth, fueled by increased market penetration, share gains, and rising incidence of prostate cancer, bolstered by updated guidelines and new commercial contracts. -
Testing Revenue
Q: What are Afirma and Decipher growth rates?
A: The team reported overall testing growth of 25%, with Decipher showing robust performance (36% revenue increase) and Afirma steadily supporting the product suite, reflecting strong clinical adoption. -
M&A Strategy
Q: What is the plan on tuck-ins/M&A?
A: Management indicated that while they remain opportunistic, the focus is firmly on growing core products—Decipher, Afirma, nasal swab, IVD, and MRD—rather than pursuing new acquisitions at present. -
MRD Development
Q: How will MRD for bladder cancer develop?
A: They are advancing their MRD platform for muscle invasive bladder cancer with an expected launch in early 2026, leveraging a novel whole-genome approach to capture a significant market opportunity. -
NIGHTINGALE Enrollment
Q: Why is NIGHTINGALE enrollment slow?
A: Management attributed the slower enrollment to typical challenges in multi-site pulmonology trials and factors beyond their control, yet affirmed that nearly 100 sites are active and the study’s scientific rigor remains paramount. -
Biopharma Pipeline
Q: Will biopharma activity grow?
A: While biopharma currently represents a small part of the revenue, management is seeing early signs or “green shoots” in related projects like MRD and GRID, though overall impact remains limited at this stage. -
Afirma TERT Impact
Q: How will TERT affect Afirma’s ASP?
A: They noted that TERT testing, reimbursed at $185, enhances the Afirma suite by adding completeness, but its impact on average selling price is modest given its selective application. -
AUA Conference
Q: What were the AUA takeaways?
A: The conference was well attended, with positive feedback on updated guidelines for Decipher; discussions reinforced the strength of the U.S. clear-based test, while international PCR launches remain future objectives. -
FDA LDT Rule
Q: Are FDA LDT rules a concern?
A: Management expressed confidence in their readiness for any regulatory changes due to robust quality systems already in place, expecting any additional costs to be offset by operational efficiencies. -
Data Monetization
Q: How will data be further monetized?
A: They explained that data currently supports their evidence generation and testing flywheel, with direct monetization not being the primary focus at this stage as they wait for more collaborative opportunities. -
Afirma GRID Demand
Q: How strong is demand for GRID?
A: Management reported that roughly 50% of physicians now request GRID, with growing interest noted in both academic settings and rural communities, thereby enhancing overall test penetration. -
Prostate Market Composition
Q: Which prostate patients drive growth?
A: They clarified that Decipher primarily targets intermediate-risk patients, with further opportunities in metastatic cases and the active surveillance group to increase overall market share.